ИННОВАЦИОННАЯ АНТИГИПЕРТЕНЗИВНАЯ ТЕРАПИЯ В СВЕТЕ ЗАВЕРШЕННЫХ НАУЧНЫХ ИССЛЕДОВАНИЙ
https://doi.org/10.20996/1819-6446-2009-5-2-89-97
Аннотация
Обсуждаются инновационные подходы к антигипертензивной фармакотерапии и преимущества современных препаратов на основе результатов рандомизированных контролируемых исследований. Обобщены рекомендации для применения препаратов различных групп, в том числе в виде комбинаций.
Об авторе
Н. А. Николаев
Омская государственная медицинская академия
Россия
Россия
644043 Омск, ул. Ленина, 12
Список литературы
1. Bhatt D.L., Steg P.G., Ohman E.M. et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006;295(2):180-9.
2. Кобалава Ж. Д., Виллевальде С.В. Является ли обучение больных фактором, повышающим эффективность контроля артериальной гипертонии? Кардиология 2007;(10):75-82.
3. Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group. JAMA 1979;242(23): 2562-71.
4. Davey Smith G., Neaton J.D., Wentworth D. et al. Mortality differences between black and white men in the USA: contribution of income and other risk factors among men screened for the MRFIT. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Lancet 1998;351(9107):934-9.
5. Davey Smith G., Bracha Y., Svendsen K.H. et al. Incidence of type 2 diabetes in the randomized multiple risk factor intervention trial. Ann Intern Med 2005;142(5):313-22.
6. Hannson L. The BBB Study: the effect of intensified antihypertensive treatment on the level of blood pressure, side-effects, morbidity and mortality in "well-treated" hypertensive patients. Behandla Blodtryck Bättre. Blood Press 1994;3(4):248-54.
7. Оганов Р.Г., Погосова Г.В., Колтунов И.Е. и др. РЕЛИФ - Регулярное лечение и профилактика - ключ к улучшению ситуации с сердечно-сосудистыми заболеваниями в России: результаты российского многоцентрового исследования. Часть 2. Кардиология 2007;(11):30-9.
8. Оганов Р.Г., Погосова Г.В., Колтунов И.Е. и др. РЕЛИФ Регулярное Лечение И профилактика - ключ к улучшению ситуации с сердечно-сосудистыми заболеваниями в России: результаты российского многоцентрового исследования. Часть 3. Кардиология 2008;(4):46-53.
9. Bianchi G., Cusi D., Gatti M. et al. A renal abnormality as a possible cause of "essential" hypertension. Lancet 1979;1(8109):173-7.
10. DiMasi J.A., Hansen R.W., Grabowski H.G. The price of innovation: new estimates of drug development costs. J Health Econ 2003;22(2):151-85.
11. Lloyd I. The R @ D revolution remains elusive. SCRIP Magazine 2004;2:52-3.
12. Николаев Н.А. Принципы полифокальной терапии больных артериальной гипертонией (тезисы). Современные наукоемкие технологии 2007;(12):80.
13. Fontanarosa P.B., Rennie D., DeAngelis C.D. Postmarketing surveillance--lack of vigilance, lack of trust. JAMA 2004;292(21):2647-50.
14. Achilladelis B., Antonakis N. The dynamics of technological innovation: the case of the pharmaceutical industry. Research policy 2001;30:535-88.
15. Безюк Н. Н. Инновационные препараты – стандарт с доказанной эффективностью и безопасностью. Доступно по адресу: http://www.health-ua.org/article/health/878.html
16. Borhani N.O., Mercuri M., Borhani P.A. et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA 1996;276(10):785-91.
17. Gosse P., Sheridan D.J., Zannad F. et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J Hypertens 2000;18(10):1465-75.
18. Mahmud A., Feely J. Antihypertensive drugs and arterial stiffness. Expert Rev Cardiovasc Ther 2003;1(1):65-78.
19. Dahlöf B., Lindholm L.H., Hansson L. et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991;338(8778): 1281-5.
20. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288(23):2981-97.
21. Moser M. Results of the ALLHAT trial: is the debate about initial antihypertensive drug therapy over? J Clin Hypertens (Greenwich) 2003;5(1):5-8.
22. Weber M. A. The ALLHAT report: a case of information and misinformation. J Clin Hypertens (Greenwich) 2003;5(1):9-13.
23. Insua J.T., Sacks H.S., Lau T.S. et al. Drug treatment of hypertension in the elderly: a meta-analysis. Ann Intern Med 1994;121(5):355-62.
24. Wikstrand J., Warnold I., Tuomilehto J. et al. Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY Study. Hypertension 1991;17(4): 579-88.
25. LaPalio L., Schork A., Glasser S., Tifft C. Safety and efficacy of metoprolol in the treatment of hypertension in the elderly. J Am Geriatr Soc 1992;40(4):354-8.
26. Zanchetti A, Rosei EA, Dal Palù, et al. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens. 1998;16(11):1667-76.
27. Cardiovascular risk and risk factors in a randomized trial of treatment based on the betablocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). The IPPPSH Collaborative Group. J Hypertens 1985;3(4):379-92.
28. Gress T.W., Nieto F.J., Shahar E. et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000;342(13):905-12.
29. Gupta A.K., Dahlof B., Dobson J. et al. Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial--Blood Pressure Lowering Arm and the relative influence of antihypertensive medication. Diabetes Care 2008;31(5):982-8.
30. Pepine C.J., Handberg E.M., Cooper-DeHoff R.M. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290(21): 2805-16.
31. Wilhelmsen L., Berglund G., Elmfeldt D. et al. Beta–blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens 1987;5(5):561-72.
32. Beevers D.G. The end of beta–blockers for uncomplicated hypertension? Lancet 2005;366(9496):1510-2.
33. New BHS-NICE guidelines (June 2006). Prescription guidelines in cardiology. Editions Frison-Roche. 2006.
34. Nur-Mammadova G.S., Mustafayev I.I. Effect of bisoprolol and nebivolol on the state of pituitary-gonadal system, penile haemodynamics and sexual function in men with hypertension (abstract). XVI European meeting on hypertension, Madrid, June 12-16, 2006. J Hypertens 2006;24 Suppl. 4:S173.
35. Czuriga I., Riecansky I., Bodnar J. et al. Comparison of the new cardioselective betablocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS). Cardiovasc Drugs Ther 2003;17(3):257-63.
36. Owada A., Suda S., Hata T., Miyake S. The effects of bisoprolol, a selective beta1- blocker, on glucose metabolism by long-term administration in essential hypertension. Clin Exp Hypertens 2001;23(4):305-16.
37. Leizorovicz A., Lechat P., Cucherat M., Bugnard F. Bisoprolol for the treatment of chronic heart failure: a meta–analysis on individual data of two placebo–controlled studies— CIBIS and CIBIS II. Cardiac Insufficiency Bisoprolol Study. Am Heart J 2002;143(2):301-7.
38. Willenheimer R., Erdmann E., Follath F. et al. Comparison of treatment initiation with bisoprolol vs. enalapril in chronic heart failure patients: rationale and design of CIBISIII. Eur J Heart Fail 2004;6(4):493-500.
39. Galatius S., Gustafsson F., Atar D., Hildebrandt P.R. Tolerability of beta-blocker initiation and titration with bisoprolol and carvedilol in congestive heart failure -a randomized comparison. Cardiology 2004;102(3):160-5.
40. González-Juanatey J.R., Alegría Ezquerra E., García Saavedra V. et al. Use of bisoprolol in heart failure. The BISOCOR observational study. Rev Esp Cardiol 2003;56(9):873-9.
41. Schuchert A. On behalf of the BISEX Investigators. Effects of bisoprolol treatment for chronic heart failure initiated and followed up by primary care physicians. Eur J Heart Fail 2005;7(4):604-11.
42. Гилман А.Г., редактор. Клиническая фармакология по Гудману и Гилману. М.: Практика, 2006.
43. Hansson L., Hedner T., Lund-Johansen P. et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000;356(9227):359-65.
44. Gong L., Zhang W., Zhu Y. et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996;14(10):1237-45.
45. Hansson L., Zanchetti A. The Hypertension Optimal Treatment (HOT) Study: 24-month data on blood pressure and tolerability. Blood Press 1997;6(5):313-7.
46. Kloner R.A., Sowers J.R., DiBona G.F. et al. Sex- and age-related antihypertensive effects of amlodipine. The Amlodipine Cardiovascular Community Trial Study Group. Am J Cardiol 1996;77(9):713-22.
47. A 12-month comparison of ACE inhibitor and CA antagonist therapy in mild to moderate essential hypertension-The GLANT Study. Study Group on Long-term Antihypertensive Therapy. Hypertens Res 1995;18(3):235-44.
48. Higashi Y., Sasaki S., Nakagawa K. et al. A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, beta-blockers and diuretic agents on reactive hyperemia in patients with essential hypertension: a multicenter study. J Am Coll Cardiol 2000;35(2):284-91.
49. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):145-53.
50. Agabiti-Rosei E., Ambrosioni E., Dal Palù C. et al. ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (ramipril cardioprotective evaluation) study on behalf of the RACE study group. J Hypertens 1995; 13(11):1325-34.
51. Wright J.T. Jr, Bakris G., Greene T. et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288(19):2421-31.
52. Kaplan N. M. The CARE Study: a postmarketing evaluation of ramipril in 11,100 patients. The Clinical Altace Real-World Efficacy (CARE) Investigators. Clin Ther 1996;18(4):658-70.
53. Curran M.P., McCormack P.L., Simpson D. Perindopril: a review of its use in patients with or at risk of developing coronary artery disease. Drugs 2006;66(2):235-55.
54. Fox K.M.; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362(9386): 782-8.
55. Topouchian J., Brisac A.M., Pannier B. et al. Assessment of the acute arterial effects of converting enzyme inhibition in essential hypertension: a double-blind, comparative and crossover study. J Hum Hypertens 1998;12(3):181-7.
56. Morgan T., Lauri J., Bertram D., Anderson A. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens 2004;17(2):118-23.
57. Scientific Committee of the PERTINENT Sub-Study, EUROPA-PERTINENT Investigators. PERTINENT--perindopril-thrombosis, inflammation, endothelial dysfunction and neurohormonal activation trial: a sub-study of the EUROPA study. Cardiovasc Drugs Ther 2003;17(1):83-91.
58. Карпов Ю.А., Деев А.Д. от имени врачей — участников исследования ПРИВИЛЕ- ГИЯ. Исследование ПРИВИЛЕГИЯ — Престариум В лечении артериальной гипертонии: гипотензивная эффективность и безопасность в сравнении с эналаприлом. Кардиология 2007;(7):35-40.
59. Карпов Ю.А., Шальнова С.А., Деев А.Д. От имени участников программы ПРЕМЬЕРА. Престариум у больных с артериальной гипертонией и ишемической болезнью сердца (или факторами риска) – безопасное достижение целевого уровня артериального давления (ПРЕМЬЕРА): результаты клинического этапа национальной программы. Кардиология 2006;(6):32–8.
60. Шальнова С.А., Деев А.Д., Карпов Ю.А. От имени участников программы ПРЕМЬЕРА. Артериальная гипертония и ИБС в амбулаторной практике врача кардиолога. Кардиоваскулярная терапия и профилактика 2006;5(2):73–80.
61. Stumpe K.O., Overlack A. A new trial of the efficacy, tolerability, and safety of angiotensin-converting enzyme inhibition in mild systemic hypertension with concomitant diseases and therapies. Perindopril Therapeutic Safety Study Group (PUTS). Am J Cardiol 1993;71(17):32E-37E.
62. Hansson L., Lindholm L.H., Niskanen L. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353(9153):611-6.
63. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317(7160):703-13.
64. Weinberger J. Morbidity and mortality after stroke--eposartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Curr Cardiol Rep 2007;9(1):5.
65. Larochelle P., Haynes B., Maron N., Dugas S. Accupril Canadian Clinical Evaluation and Patient Teaching. Clin Ther 1994;16(5):838-53.
66. Hansson L., Forslund T., Höglund C. et al. Fosinopril versus enalapril in the treatment of hypertension: a double-blind study in 195 patients. J Cardiovasc Pharmacol 1996;28(1):1-5.
67. Marin R., Ruilope L.M., Aljama P. et al. A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease. J Hypertens 2001;19(10):1871-6.
68. Wachtell K., Lehto M., Gerdts E. et al. Angiotensin II receptor blockade reduces newonset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005;45(5):712-9.
69. Maggioni A.P., Latini R., Carson P.E et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (ValHeFT). Am Heart J 2005;149(3):548-57.
70. Cohn J.N., Tognoni G.; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345(23):1667-75.
71. Mochizuki S., Dahlöf B., Shimizu M. et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, openlabel, blinded endpoint morbidity-mortality study. Lancet 2007;369(9571):1431-9.
72. Klingbeil A.U., Schneider M., Martus P. et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003;115 (1):41-46.
73. Deedwania P.C., Fonseca V.A. Diabetes, prediabetes, and cardiovascular risk: shifting the paradigm. Am J Med 2005;118(9):939-47.
74. Elliott W.J., Meyer P.M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007;369(9557):201-7.
75. Weycker D., Edelsberg J., Vincze G. et al. Risk of diabetes in a real-world setting among patients initiating antihypertensive therapy with valsartan or amlodipine. J Hum Hypertens 2007;21(5):374-80.
76. Atkins R.C., Briganti E.M., Lewis J.B. et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005;45(2):281-7.
77. Hollenberg N.K., Parving H.H., Viberti G. et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens 2007;25(9):1921-6.
78. Viberti G, Wheeldon NM; MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002;106(6):672-8.
79. Brown D.W., Giles W.H., Croft J.B. Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension. Am Heart J 2000;140(6):848-56.
80. Fossum E., Moan A., Kjeldsen S.E. et al. The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study. J Am Coll Cardiol 2005;46(5):770-5.
81. Nichols WW, O'Rourke MF. McDonald's blood flow in arteries: theoretic, experimental and clinical principles. 5th ed. London: Edward Arnold, 2005.
82. Brenner B.M., Cooper M.E., de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345(12):861-9.
83. Pfeffer M.A., McMurray J.J., Velazquez E.J. et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349(20):1893-906.
84. Parving H.H., Lehnert H., Bröchner-Mortensen J. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345(12):870-8.
85. Gradman A.H., Lewin A., Bowling B.T. et al. Comparative effects of candesartan cilexetil and losartan in patients with systemic hypertension. Candesartan Versus Losartan Efficacy Comparison (CANDLE) Study Group. Heart Dis 1999;1(2):52-7.
86. Granger C.B., McMurray J.J., Yusuf S. et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362(9386):772-6.
87. Kloner R.A., Weinberger M., Pool J.L. et al. Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators. Am J Cardiol 2001;87(6):727-31.
88. Cuspidi C., Muiesan M.L., Valagussa L. et al. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens 2002;20(11):2293-300.
89. Teo K., Yusuf S., Sleight P. et al. The ONTARGET /TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004;148(1):52-61.
90. ONTARGET Investigators, Yusuf S., Teo K.K., Pogue J. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358(15):1547-59.
91. Asmar R.G., Benetos A., Chaouche-Teyara K. et al. Comparison of effects of felodipine versus hydrochlorothiazide on arterial diameter and pulse-wave velocity in essential hypertension. Am J Cardiol 1993;72(11):794-8.
92. Kool M.J., Lustermans F.A, Breed J.G. Effect of perindopril and amiloride/hydrochlorothiazide on haemodynamics and vessel wall properties of large arteries. J Hypertens Suppl 1993;11(5):S362-3.
93. Pitt B., Byington R.P., Furberg C.D. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000;102(13):1503-10.
94. Brown M.J., Palmer C.R., Castaigne A. et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000;356(9227):366-72.
95. Brenner B.M., Cooper M.E., de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345(12):861-9.
96. Muiesan M.L., Salvetti M., Monteduro C. et al. Effect of treatment on flow-dependent vasodilation of the brachial artery in essential hypertension. Hypertension 1999;33(1 Pt 2):575-80.
97. Terpstra W.F., May J.F., Smit A.J. et al. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. J Hypertens 2001;19(2):303-9.
98. Csaba F. a HAMLET Vizsgálók nevében. A lisinopril és az amlodipin kombinációjának előnyei az antihypertensiv terápiában. A Hypertoniában adott AMlodipin 5 mg és Lisinopril 10 mg tabletták hatékonyságának és tolerálhatóságának összehasonlító vizsgálata külön és Együtt alkalmazott Terápiaként (HAMLET). Multicentrikus vizsgálat eredményei. Hypertonia es nephrologia 2004;8(2):72–8.
99. Páll D., Katona E., Juhász M., Paragh G. Prevention of target organ damage with modern antihypertensive agents. Orv Hetil 2006;147(32): 1505-11.
100. Dahlöf B., Pennert K., Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 1992;5(2):95-110.
101. Sever P. on behalf of the ASCOT investigators. ASCOT-LLA revisited: Interaction of antihypertensive and lipid-lowering therapy. American Heart Association Scientific Sessions; November 14, 2005; Dallas, TX.
102. Dahlöf B., Sever P.S., Poulter N.R. et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366(9489):895-906.
103. Sever P.S., Dahlöf B., Poulter N.R. et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361(9364):1149-58.
104. Poulter N.R., Wedel H., Dahlöf B. et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005;366(9489):907-13.
105. Herlitz H., Harris K., Risler T. et al. The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study. Nephrol Dial Transplant 2001;16(11):2158-65.
106. Kjeldsen S.E., Jamerson K.A., Bakris G.L. et al. Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study. Blood Press 2008;17(1):7-17.
107. Applegate W.B., Cohen J.D., Wolfson P. et al. Evaluation of blood pressure response to the combination of enalapril (single dose) and diltiazem ER (four different doses) in systemic hypertension. Am J Cardiol 1996; 78(1):51-5.
108. Smith T.R., Philipp T., Vaisse B. et al. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens (Greenwich) 2007;9(5):355-64.
109. Lindholm L.H., Persson M., Alaupovic P. et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003;21(8):1563-74.
110. Poldermans D., Glazes R., Kargiannis S. et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther 2007;29(2):279-89.
111. Patel A; ADVANCE Collaborative Group, et al. Effects of fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370(9590):829-40.
112. London G.M., Asmar R.G., O'Rourke M.F. et al. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol 2004; 43(1):92-9.
113. PROGRESS Collaborative Group. Randomised trial of a perindopril-based bloodpressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358(9287): 1033-41.
114. Mogensen C.E., Neldam S., Tikkanen I. et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321(7274):1440-4.
115. Higashiura K., Ura N., Miyazaki Y., Shimamoto K. Effect of an angiotensin II receptor antagonist, candesartan, on insulin resistance and pressor mechanisms in essential hypertension. J Hum Hypertens 1999;13 Suppl 1:S71-4.
116. Nakao N., Yoshimura A., Morita H. et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003;361(9352): 117-24.
117. MacKay J.H., Arcuri K.E., Goldberg A.I. et al. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch Intern Med 1996;156(3):278-85.
118. MRC trial of treatment of mild hypertension. Br Med J (Clin Res Ed) 1985;291(6490):277-8.
119. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288(23): 2981-97.
120. Kjeldsen S.E., Dahlöf B., Devereux R.B. et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002;288(12):1491-8.
121. Weber M.A., Julius S., Kjeldsen S.E. et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004;363(9426):2049-51.
122. Dahlöf B., Devereux R.B., Kjeldsen S.E. et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359(9311):995-1003.
123. Nichols W. W. Clinical measurement of arterial stiffness obtained from noninvasive pressure waveforms. Am J Hypertens 2005;18(1 Pt 2):3S-10S.
Рецензия
Для цитирования:
Николаев Н.А. ИННОВАЦИОННАЯ АНТИГИПЕРТЕНЗИВНАЯ ТЕРАПИЯ В СВЕТЕ ЗАВЕРШЕННЫХ НАУЧНЫХ ИССЛЕДОВАНИЙ. Рациональная Фармакотерапия в Кардиологии. 2009;5(2):89-97. https://doi.org/10.20996/1819-6446-2009-5-2-89-97
For citation:
Nikolaev N.A. INNOVATIVE ANTIHYPERTENSIVE THERAPY IN THE LIGHT OF COMPLETED CLINICAL TRIALS. Rational Pharmacotherapy in Cardiology. 2009;5(2):89-97. (In Russ.) https://doi.org/10.20996/1819-6446-2009-5-2-89-97
Просмотров:
793
Послать статью по эл. почте 